Tolvaptan has been used in Europe and America since the late 2000s in patients with syndrome of inappropriate secretion of antidiuretic hormone, and several studies have reported its effectiveness in heart failure, and cirrhosis with hyponatremia [7, 8]. Here, AVP is linked to Down syndrome.